Literature DB >> 26141677

Computational prediction and biochemical characterization of novel RNA aptamers to Rift Valley fever virus nucleocapsid protein.

Mary Ellenbecker1, Jeremy St Goddard1, Alec Sundet2, Jean-Marc Lanchy1, Douglas Raiford3, J Stephen Lodmell4.   

Abstract

Rift Valley fever virus (RVFV) is a potent human and livestock pathogen endemic to sub-Saharan Africa and the Arabian Peninsula that has potential to spread to other parts of the world. Although there is no proven effective and safe treatment for RVFV infections, a potential therapeutic target is the virally encoded nucleocapsid protein (N). During the course of infection, N binds to viral RNA, and perturbation of this interaction can inhibit viral replication. To gain insight into how N recognizes viral RNA specifically, we designed an algorithm that uses a distance matrix and multidimensional scaling to compare the predicted secondary structures of known N-binding RNAs, or aptamers, that were isolated and characterized in previous in vitro evolution experiment. These aptamers did not exhibit overt sequence or predicted structure similarity, so we employed bioinformatic methods to propose novel aptamers based on analysis and clustering of secondary structures. We screened and scored the predicted secondary structures of novel randomly generated RNA sequences in silico and selected several of these putative N-binding RNAs whose secondary structures were similar to those of known N-binding RNAs. We found that overall the in silico generated RNA sequences bound well to N in vitro. Furthermore, introduction of these RNAs into cells prior to infection with RVFV inhibited viral replication in cell culture. This proof of concept study demonstrates how the predictive power of bioinformatics and the empirical power of biochemistry can be jointly harnessed to discover, synthesize, and test new RNA sequences that bind tightly to RVFV N protein. The approach would be easily generalizable to other applications.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aptamers; Nucleocapsid protein; RNA structure prediction; Rift Valley fever virus; Viral inhibition

Mesh:

Substances:

Year:  2015        PMID: 26141677      PMCID: PMC4604023          DOI: 10.1016/j.compbiolchem.2015.06.005

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  11 in total

1.  UNAFold: software for nucleic acid folding and hybridization.

Authors:  Nicholas R Markham; Michael Zuker
Journal:  Methods Mol Biol       Date:  2008

Review 2.  Nucleoproteins and nucleocapsids of negative-strand RNA viruses.

Authors:  Rob W H Ruigrok; Thibaut Crépin; Dan Kolakofsky
Journal:  Curr Opin Microbiol       Date:  2011-08-06       Impact factor: 7.934

3.  Inhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin.

Authors:  Mary Ellenbecker; Jean-Marc Lanchy; J Stephen Lodmell
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

4.  Outbreak of Rift Valley fever--Saudi Arabia, August-October, 2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-10-13       Impact factor: 17.586

5.  Characterization of RNA aptamers directed against the nucleocapsid protein of Rift Valley fever virus.

Authors:  Mary Ellenbecker; Leila Sears; Ping Li; Jean-Marc Lanchy; J Stephen Lodmell
Journal:  Antiviral Res       Date:  2012-01-10       Impact factor: 5.970

6.  RSV604, a novel inhibitor of respiratory syncytial virus replication.

Authors:  Joanna Chapman; Elizabeth Abbott; Dagmar G Alber; Robert C Baxter; Sian K Bithell; Elisa A Henderson; Malcolm C Carter; Phil Chambers; Ann Chubb; G Stuart Cockerill; Peter L Collins; Verity C L Dowdell; Sally J Keegan; Richard D Kelsey; Michael J Lockyer; Cindy Luongo; Pilar Najarro; Raymond J Pickles; Mark Simmonds; Debbie Taylor; Stan Tyms; Lara J Wilson; Kenneth L Powell
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

7.  Vector competence of selected African mosquito (Diptera: Culicidae) species for Rift Valley fever virus.

Authors:  Michael J Turell; Kenneth J Linthicum; Lisa A Patrican; F Glyn Davies; Alladin Kairo; Charles L Bailey
Journal:  J Med Entomol       Date:  2008-01       Impact factor: 2.278

8.  The persistence of rift valley fever in the Jazan region of Saudi Arabia.

Authors:  A A Elfadil; K A Hasab-Allah; O M Dafa-Allah; A A Elmanea
Journal:  Rev Sci Tech       Date:  2006-12       Impact factor: 1.181

9.  Structure of severe fever with thrombocytopenia syndrome virus nucleocapsid protein in complex with suramin reveals therapeutic potential.

Authors:  Lianying Jiao; Songying Ouyang; Mifang Liang; Fengfeng Niu; Neil Shaw; Wei Wu; Wei Ding; Cong Jin; Yao Peng; Yanping Zhu; Fushun Zhang; Tao Wang; Chuan Li; Xiaobing Zuo; Chi-Hao Luan; Dexin Li; Zhi-Jie Liu
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

10.  Fast pairwise structural RNA alignments by pruning of the dynamical programming matrix.

Authors:  Jakob H Havgaard; Elfar Torarinsson; Jan Gorodkin
Journal:  PLoS Comput Biol       Date:  2007-08-20       Impact factor: 4.475

View more
  4 in total

Review 1.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

Review 2.  Aptamers isolated against mosquito-borne pathogens.

Authors:  Tholasi Nadhan Navien; Tzi Shien Yeoh; Andrew Anna; Thean-Hock Tang; Marimuthu Citartan
Journal:  World J Microbiol Biotechnol       Date:  2021-07-09       Impact factor: 3.312

Review 3.  Transcription and replication mechanisms of Bunyaviridae and Arenaviridae L proteins.

Authors:  François Ferron; Friedemann Weber; Juan Carlos de la Torre; Juan Reguera
Journal:  Virus Res       Date:  2017-01-27       Impact factor: 3.303

Review 4.  Aptamers for Anti-Viral Therapeutics and Diagnostics.

Authors:  Tae-Hyeong Kim; Seong-Wook Lee
Journal:  Int J Mol Sci       Date:  2021-04-17       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.